Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Eli Lilly And Co (LLY) Price & Performance

First Trust NASDAQ Cybersecurity ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Cybersecurity ETF vs Eli Lilly And Co — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $93.18, while Eli Lilly And Co trades at $1,155.31 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while First Trust NASDAQ Cybersecurity ETF pays none. Which is the better fit depends on your goals.

CIBRLLY
52-Week High
$94.73$1.24K
52-Week Low
$60.74$625.65
Market Cap
$1.03T
Sector
Health
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Cybersecurity ETF

CIBR trades at $91.84, down 0.04% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF has demonstrated strong performance, outperforming the S&P 500 by a three-to-one margin year-to-date, driven by robust cybersecurity spending trends. A dividend of $0.07 is scheduled for June 30, 2026. Recent news highlights institutional accumulation and positive momentum in the cybersecurity sector.

The outlook for CIBR is supported by growing global cybersecurity expenditures, projected to exceed $300 billion in 2026, and AI-driven demand. Risks include sector volatility and concentrated tech exposure. Analyst sentiment is positive, with recent upgrades citing reasonable valuation and secular growth, though investors should weigh high institutional interest against market cyclicality.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY